Drug – bio-affecting and body treating compositions – Solid synthetic organic polymer as designated organic active...
Reexamination Certificate
2006-04-25
2006-04-25
Page, Thurman K. (Department: 1618)
Drug, bio-affecting and body treating compositions
Solid synthetic organic polymer as designated organic active...
C424S400000, C424S439000, C424S451000, C424S464000
Reexamination Certificate
active
07033582
ABSTRACT:
The present invention involves the administration of Copolymer 1 (glatiramer acetate) to treat inflammatory, non-autoimmune central nervous system (CNS) diseases, alleviate the symptoms thereof, inhibit the activity of matrix metalloproteinases and suppress cytokine production by T lymphocytes.
REFERENCES:
patent: 3849550 (1974-11-01), Teitelbaum et al.
patent: 3991210 (1976-11-01), Shea
patent: 4129666 (1978-12-01), Wizerkaniuk
patent: 4339431 (1982-07-01), Gaffar
patent: 5204099 (1993-04-01), Barbier et al.
patent: 5554372 (1996-09-01), Hunter
patent: 5583031 (1996-12-01), Stern
patent: 5591629 (1997-01-01), Rodriguez et al.
patent: 5623052 (1997-04-01), McLean et al.
patent: 5627206 (1997-05-01), Hupe et al.
patent: 5688117 (1997-11-01), May et al.
patent: 5719296 (1998-02-01), Acton, III et al.
patent: 5734023 (1998-03-01), Nag et al.
patent: 5800808 (1998-09-01), Konfino et al.
patent: 5858964 (1999-01-01), Aharoni et al.
patent: 5886156 (1999-03-01), McLean et al.
patent: 5958927 (1999-09-01), Peglion et al.
patent: 5965600 (1999-10-01), Sato et al.
patent: 5981589 (1999-11-01), Konfino et al.
patent: 6024981 (2000-02-01), Khankari et al.
patent: 6048898 (2000-04-01), Konfino et al.
patent: 6054430 (2000-04-01), Konfino et al.
patent: 6162800 (2000-12-01), Dolle et al.
patent: 6214791 (2001-04-01), Arnon et al.
patent: 6342476 (2002-01-01), Konfino et al.
patent: 6362161 (2002-03-01), Konfino et al.
patent: 6514938 (2003-02-01), Gad et al.
patent: 6620847 (2003-09-01), Konfino et al.
patent: 6800285 (2004-10-01), Rodriguez et al.
patent: 6800287 (2004-10-01), Gad et al.
patent: 6844314 (2005-01-01), Eisenbach-Schwartz et al.
patent: 2001/0055568 (2001-12-01), Gilbert et al.
patent: 2002/0037848 (2002-03-01), Eisenbach-Schwartz et al.
patent: 2002/0055466 (2002-05-01), Aharoni et al.
patent: 2002/0077278 (2002-06-01), Yong et al.
patent: 2002/0107388 (2002-08-01), Vanderbark et al.
patent: 2003/0004099 (2003-01-01), Eisenbach-Schwartz et al.
patent: 2003/0170729 (2003-09-01), Klinger
patent: 2004/0006022 (2004-01-01), Strominger et al.
patent: 2004/0106554 (2004-06-01), Konfino et al.
patent: 2005/0019322 (2005-01-01), Rodriguez et al.
patent: 2005/0038233 (2005-02-01), Gad et al.
patent: 0383620 (1990-08-01), None
patent: 0359783 (1995-11-01), None
patent: WO 9202543 (1992-02-01), None
patent: WO 9403484 (1994-02-01), None
patent: WO 9426774 (1994-11-01), None
patent: WO9526980 (1995-10-01), None
patent: WO 9531990 (1995-11-01), None
patent: WO9531997 (1995-11-01), None
patent: WO 9533475 (1995-12-01), None
patent: WO 9830227 (1998-07-01), None
patent: WO 8810120 (1998-12-01), None
patent: WO0005249 (2000-02-01), None
patent: WO 0005249 (2000-02-01), None
patent: WO 0005250 (2000-02-01), None
patent: WO 0018794 (2000-04-01), None
patent: WO 0020010 (2000-04-01), None
patent: WO 0027417 (2000-05-01), None
patent: WO0152878 (2001-07-01), None
patent: WO0160392 (2001-08-01), None
patent: WO0185797 (2001-11-01), None
patent: WO0193828 (2001-12-01), None
patent: WO0193893 (2001-12-01), None
patent: WO 0197846 (2001-12-01), None
patent: WO02076503 (2002-10-01), None
patent: WO03048935 (2003-06-01), None
Teitelbaum et al., “Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide”,Israel J. Med. Sci.,1971, 7, 630-631 (Abstract).
Teitelbaum, et al., “Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptid”,Eur. J. Immonol.,1971, 1, 242-248.
Arnon, et al., “Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Copolymer Immunological Cross Reactive with Basic Encephalitogen”,Israel J. Med. Sci.,1972, 8, 1759-1760.
Teitelbaum et al., “Protection Against Experimental Allergic Encephalomyelitis”,Nature,1972, 240, 564-566.
Webb et al., “Further Studies on the Suppression of Experimental Allergic Encephalomyelitis by Snythetic Copolymer”,Israel J. Med. Sci.,1972, 8, 656-657.
Teitelbaum et al., “Suppression Experimental Allergic Encephalomyelitis with Basic Polymers”,Eur. J. Immunol.,1973, 3, 273-279.
Webb, et al., “In Vivo and in Vitro Immunological Cross-reactions between Basic Encephalitogen and Synthetic Basic Polypeptides Capable of Suppressing Experimental Allergic Encephalomyelitis”, Eur. J. Immunol., 1973, 3, 279-286.
Teitelbaum et al., “Dose-response Studies on Experimental Allergic Encephalomyelitis Suppression by COP-I”,Israel J. Med. Sci.,1974, 10(9), 1172-1173.
Teitelbaum, et al., “Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer”,Clin. Immunol. Immunopath.,1974, 3, 256-262.
Webb et al., “Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer”,Israel J. Med. Sci.,1975, 11, 1388 (Abstract).
Webb, et al., “Molecular Requirements Involved in Suppression of EAE by Synthetic Basic Copolymers of Amino Acids”,Immunochem.,1976, 13, 333-337.
Abramsky, et al., “Effect of a Synthetic Polypeptide (COP-1) on Patients with Multiple Sclerosis and with Acute Disseminated Encephalomyelitis”,J. Neurol. Sci.,1977, 31, 433-438.
Teitelbaum, et al., “suppression Experimental Allergic Encephalomyelitis in Baboons by Cop 1”,Israel J. Med. Sci.,1977, 13, 1038 (Abstract).
Arnon, et al., “Suppression of EAE in Baboons by a Synthetic Polymer of Amino Acids”,Neurol.,1978, 28, 336 (Abstract).
Sela, et al., “Experimental Allergic Encephalomyelitis” inMenarini Series on Immunopathology,vol. 1,First Symposium of Organ Specific Autoimmunity,Cremona, Italy, Jun., 1977, (Miescher P.A. ed., Schwabe Co., Basel, 1978), 9-21.
Alvord, et al., “Myelin Basic Protein Treatment of Experimental Allergic Encephalomyelitis in Monkeys”,Ann. Neurol.,1979, 6, 469-473.
Keith, et al., “The Effect of COP 1, a Synthetic Polypeptide, on Chronic Relapsing Experimental Allergic Encephalomyelitis in Guinea Pigs”J. Neurol. Sci.,1979, 42, 267-274.
Lando, et al., “Effect of Cyclophosphamide on Suppressor Cell Activity in Mice Unresponsive to EAE”,J. Immunol.,1979, 123, 2156-2160. (Abstract).
Lando, et al., “Experimental Allergic Encephalomyelitis in Mice—Suppresion and Prevention with COP-1”,Israel J. Med. Sci.,1979, 15, 868-869 (Abstract).
Teitelbaum, et al., “Blocking of Sensitization to Encephalitogenic Basic Protein in Vitro by Synthetic Basic Copolymer (COP 1)” inCell Biology and Immunology of Leukocyte Function(Academic Press, New York, 1979) 681-685.
Teitelbaum, “Suppression of Experimental Allergic Encephalomylitis with a Synthetic Copolymer—Relevance to Multiple Sclerosis”, inHumoral Immunity in Neurological Diseases(Karcher D., Lowenthal A. & Strosberg A.D., eds., Plenum Publishing Corp., 1979) 609-613.
Arnon, et al., “Desensitization of Experimental Allergic Encephalomyelitits with Synthetic Peptide Analogues” inThe Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis(Academic Prss, New York, 1980) 105-107.
Arnon, “A Synthetic Copolymer of Amino Acids in a Clinical Trial for MS Therapy” inProgress in Multiple Sclerosis Research(Bauer, Ritter, eds., Springer Verlag New York, 1980) 416-418.
Bornstein, et al., “Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results”,ann. Neurol.,1980, 8, 117 (Abstract).
Bornstein, et al., “Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results”,Trans. Am. Neurol. Assoc.,1980 105, 348-350.
McDermott, et al., “Antigen-induced Suppression of Experimental Allergic Neuritis in the Guinea Pig”,J. Neurol. Sci.,1980, 46, 137-143.
Arnon, “Experimental Allergic Encephalomyelitis—Susceptibility and Suppression”,Immunological Rev.,1981, 55, 5-30.
Bornstein, et al., “Multiple Sclerosis: Trial of a Synthetic Polypeptide”,Ann. Neurol.,1982, 11, 317-319
Chabot Sophie
Yong V. Wee
Cooper & Dunham LLP
Oh Simon
Page Thurman K.
Teva Pharmaceutical Industries Ltd.
White, Esq. John P.
LandOfFree
Use of glatiramer acetate (copolymer 1) in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of glatiramer acetate (copolymer 1) in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of glatiramer acetate (copolymer 1) in the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3612383